INTRODUCTION: Copayments are intended to decrease third party expenditure on pharmaceuticals, particularly those regarded as less essential. However, copayments are associated with decreased use of all medicines. Publicly insured populations encompass some vulnerable patient groups such as older individuals and low income groups, who may be especially susceptible to medication non-adherence when required to pay. Non-adherence has potential consequences of increased morbidity and costs elsewhere in the system. OBJECTIVE: To quantify the risk of non-adherence to prescribed medicines in publicly insured populations exposed to copayments. METHODS: The population of interest consisted of cohorts who received public health insurance. The interven...
While pharmaceutical copayments are effective in containing system-level expenditures, the increased...
While pharmaceutical copayments are effective in containing system-level expenditures, the increased...
PURPOSE: We assessed the impact of the introduction of a €0.50 prescription copayment, and its incre...
<div><p>Introduction</p><p>Copayments are intended to decrease third party expenditure on pharmaceut...
Copayments are intended to decrease third party expenditure on pharmaceuticals, particularly those r...
INTRODUCTION: Copayments are intended to decrease third party expenditure on pharmaceuticals, partic...
Introduction: Copayments are intended to decrease third party expenditure on pharmaceuticals, partic...
Introduction: Copayments are intended to decrease third party expenditure on pharmaceuticals, partic...
Copayment policies aim to reduce the burden of medication expenditure but may affect adherence and g...
Background: Prescription medication copayments can be a financial burden to many patients. When pati...
Background: Prescription medication copayments can be a financial burden to many patients. When pati...
BackgroundStatins remain a fundamental component of pharmacologic therapy for hyperlipidemia. Health...
Rising pharmaceutical expenditures have led to the use of cost-sharing measures. The authors underto...
This paper estimates the effects of a large employer\u27s value-based insurance initiative designed ...
Copayments for prescriptions may increase morbidity and mortality via reductions in adherence to med...
While pharmaceutical copayments are effective in containing system-level expenditures, the increased...
While pharmaceutical copayments are effective in containing system-level expenditures, the increased...
PURPOSE: We assessed the impact of the introduction of a €0.50 prescription copayment, and its incre...
<div><p>Introduction</p><p>Copayments are intended to decrease third party expenditure on pharmaceut...
Copayments are intended to decrease third party expenditure on pharmaceuticals, particularly those r...
INTRODUCTION: Copayments are intended to decrease third party expenditure on pharmaceuticals, partic...
Introduction: Copayments are intended to decrease third party expenditure on pharmaceuticals, partic...
Introduction: Copayments are intended to decrease third party expenditure on pharmaceuticals, partic...
Copayment policies aim to reduce the burden of medication expenditure but may affect adherence and g...
Background: Prescription medication copayments can be a financial burden to many patients. When pati...
Background: Prescription medication copayments can be a financial burden to many patients. When pati...
BackgroundStatins remain a fundamental component of pharmacologic therapy for hyperlipidemia. Health...
Rising pharmaceutical expenditures have led to the use of cost-sharing measures. The authors underto...
This paper estimates the effects of a large employer\u27s value-based insurance initiative designed ...
Copayments for prescriptions may increase morbidity and mortality via reductions in adherence to med...
While pharmaceutical copayments are effective in containing system-level expenditures, the increased...
While pharmaceutical copayments are effective in containing system-level expenditures, the increased...
PURPOSE: We assessed the impact of the introduction of a €0.50 prescription copayment, and its incre...